Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2016

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):

		Three Months Ended September 30,				Nine Months Ended September 30,
Agreement	Deliverable	2016		2015		2016		2015
Japan	License	$	3,041	$	414	$	3,159	$	942
	Milestones		—		—		10,000		—
	Total license and milestone revenue		3,041	$	414	$	13,159	$	942
	Collaboration services revenue*		144	$	57	$	151	$	157

When and if available compounds, manufacturing — clinical supplies and committee services have each been identified as separate units of accounting with standalone value and amounts allocable to these elements have been recognized and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through September 30, 2016		Deferred Revenue at September 30, 2016		Total Consideration Through September 30, 2016
License	$	45,403	$	—	$	45,403
When and if available compounds		20		26		46
Manufacturing--clinical supplies		2,108		—		2,108
Committee services		20		—		20
Total license and collaboration services revenue	$	47,551	$	26	$	47,577

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Three Months Ended September 30,				Nine Months Ended September 30,
Agreement	Deliverable	2016		2015		2016		2015
Europe	License	$	1,330	$	4,706	$	7,568	$	13,730
	Milestones		—		—		—		—
	Total license and milestone revenue		1,330		4,706		7,568		13,730
	Collaboration services revenue*	$	292	$	812	$	963	$	2,065

When and if available compounds, manufacturing — clinical supplies, development services — in progress at the time of signing of the agreement, and committee services have each been identified as a separate unit of accounting with standalone value and amounts allocable to these units have been recognized in revenue as services are performed and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through September 30, 2016		Deferred Revenue at September 30, 2016		Total Consideration Through September 30, 2016
License	$	409,012	$	—	$	409,012
When and if available compounds		362		417		779
Manufacturing--clinical supplies		9,797		—		9,797
Development services--in progress		32,770		—		32,770
Committee services		283		—		283
Total license and collaboration services revenue	$	452,224	$	417	$	452,641

U.S./RoW [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Three Months Ended September 30,				Nine Months Ended September 30,
Agreement	Deliverable	2016		2015		2016		2015
U.S. / RoW and China	License	$	16,496	$	7,925	$	93,075	$	101,758
	Milestones		—		—		—		15,000
	Total license and milestone revenue		16,496		7,925		93,075		116,758
	Collaboration services revenue*		8,784		5,614		32,723		22,694
	China single unit of accounting**	$	—	$	—	$	—	$	—

Co-development, information sharing, and committee services have been combined into a single unit of accounting because the requirements to share information and serve on committees are useful only in combination with the development services, and because all three items are delivered over the same period while manufacturing — clinical supplies has been identified as a separate unit of accounting with standalone value and amounts allocable to this unit of accounting have been recognized and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

All revenues attributable to the China unit of accounting are deferred until all deliverables are met. The China license and collaboration services elements have been combined into a single unit of accounting and consideration allocable to this unit is being deferred due to FibroGen’s retention of manufacturing rights and lack of standalone value.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the U.S./RoW Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through September 30, 2016		Deferred Revenue at September 30, 2016		Total Consideration Through September 30, 2016
License	$	382,842	$	—	$	382,842
Co-development, information sharing & committee services		82,759		33,638		116,397
Manufacturing--clinical supplies		358		40		398
China-single unit of accounting		—		78,472		78,472
Total license and collaboration services revenue	$	465,959	$	112,150	$	578,109